secwatch.observer — SEC 8-K summary
======================================

Issuer:     LivaNova PLC (LIVN)
CIK:        0001639691
Form:       8-K
Filed at:   2024-07-31T23:59:59+00:00
Accession:  0001639691-24-000105
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LivaNova Q2 revenue $318.6M (+8.4%), adj. EPS $0.93; raises FY outlook
----------------------------------------------------------------------

- Q2 revenue $318.6M, up 8.4% reported and 9.6% constant-currency; ex-ACS wind down, constant-currency growth 10.8%.
- GAAP diluted EPS $0.30; adjusted diluted EPS $0.93.
- Raised full-year 2024 revenue and adjusted diluted EPS guidance.
- Franco Poletti named President of Cardiopulmonary Business Unit, effective August 1, 2024.
- Plans to pursue CMS coverage for VNS Therapy in RECOVER patient population; reducing 2025 investment in difficult-to-treat depression.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1639691/000163969124000105/0001639691-24-000105-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1639691/000163969124000105/livn-20240731.htm
  HTML page:      https://secwatch.observer/filing/0001639691-24-000105

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer